Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fushengong decoction (FSGD) is a Traditional Chinese Medicine (TCM) herbal formula primarily developed and studied at the Yongchuan Traditional Chinese Medicine Hospital affiliated with Chongqing Medical University for the treatment of chronic renal failure (CRF). FSGD contains several bioactive small molecules, including quercetin, formononetin, and pachymic acid. Its therapeutic effects are mediated through the regulation of multiple signaling pathways; specifically, it activates the PTEN pathway while inhibiting the PI3K/AKT/NF-κB and TGF-β1 pathways, thereby reducing renal parenchyma damage and interstitial fibrosis. Additionally, FSGD has been shown to increase the expression of nephrin mRNA in renal tissues, which helps maintain the integrity of the glomerular filtration barrier by protecting podocytes. Clinical studies have demonstrated that FSGD, when combined with Western medicine, significantly improves renal function markers such as serum creatinine, blood urea nitrogen, and cystatin C.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fushengong decoction.